ecrin-mdr-crcClinical2019IPD Sharing (as of February 2022): NoOvarian CancerLeukemia, MyeloidTriple Negative Breast NeoplasmsColorectal CancerSmall Cell Lung CarcinomaTriple-negative Breast CancerSmall-cell Lung CancerLeukemia, Myeloid, AcuteAcute Myelogenous LeukemiaOvarian CancerLeukemia, MyeloidTriple Negative Breast NeoplasmsColorectal CancerSmall Cell Lung CarcinomaTriple-negative Breast CancerSmall-cell Lung CancerLeukemia, Myeloid, AcuteAcute Myelogenous LeukemiaInterventionalhttps://newmdr.ecrin.org/Study/2291112United States6Checkpoint inhibitorSLS-001Combination immunotherapyOff-the-shelf vaccinePeptide vaccineImmuno-oncologyWT1-expressing tumorsPembrolizumabPD1 inhibitorGalinpepimut-SMultivalentHLA alleleHeterocliticWT1 analog peptide vaccineWT1 vaccineECRIN MDRActive, not recruitingfalseGalinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersTo evaluate the safety and tolerability of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers. Patients will be followed long-term for Overall Survival (OS) and safety. The study will enroll approximately 90 patients and maximum study treatment duration is approximately 2.13 years.2019-06-152291112NCT03761914